Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Epidemiology forecast- 2030

DelveInsight's 'Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Epidemiology Forecast to 2030
' report delivers an in-depth understanding of the disease, historical and forecasted Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017-2030

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Understanding
The DelveInsight Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
epidemiology report gives a thorough understanding of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
in the US, Europe, and Japan. The report covers the detailed information of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
epidemiology scenario in seven major countries (US, EU5, and Japan).

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology Perspective by DelveInsight
The Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Detailed Epidemiology Segmentation
The Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
epidemiology covered in the report provides historical as well as forecasted Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
• The Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology Report and Model provide an overview of the risk factors and global trends of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

• The report provides the segmentation of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
epidemiology

Report Highlights
• 11-Year Forecast of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
epidemiology
• 7MM Coverage
• Total Cases of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

• Total Cases of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
according to segmentation
• Diagnosed cases of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)


KOL- Views
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
?
• What are the key findings pertaining to the Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
• What would be the total number of patients of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
across the 7MM during the forecast period (2017-2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
• What is the disease risk, burden and unmet needs of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
?
• What are the currently available treatments of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
?

Reasons to buy
• The Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
market
• Quantify patient populations in the global Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
therapeutics in each of the markets covered
• Understand the magnitude of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
population by its epidemiology
• The Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Please Note: It will take 5-7 business days to complete the report upon order confirmation.


1. Key Insights
2. Executive Summary of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
3. Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
: Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Treatment and Management
6.2. Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
Table 1 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in 7MM (2017-2030)
Table 2 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in 7MM (2017-2030)
Table 3 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in the United States (2017-2030)
Table 4 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in Germany (2017-2030)
Table 6 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in France (2017-2030)
Table 8 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in France (2017-2030)
Table 9 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in Italy (2017-2030)
Table 10 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in Spain (2017-2030)
Table 12 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in the United Kingdom (2017-2030)
Table 14 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Table 15 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in Japan (2017-2030)
Table 16 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 1 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in 7MM (2017-2030)
Figure 2 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in 7MM (2017-2030)
Figure 3 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in the United States (2017-2030)
Figure 4 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in Germany (2017-2030)
Figure 6 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in France (2017-2030)
Figure 8 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in Italy (2017-2030)
Figure 10 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in Spain (2017-2030)
Figure 12 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in the United Kingdom (2017-2030)
Figure 14 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Figure 15 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Epidemiology in Japan (2017-2030)
Figure 16 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Diagnosed and Treatable Cases in Japan (2017-2030)
*The table of contents is not exhaustive; will be provided in the final report

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook